Drug Trial Radar · NCT05243251
Olanzapine Anorexia Cachexia
Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
164
Actual
Start
Dec 25, 2021
Primary completion
Nov 21, 2022
Study completion Dec 14, 2022
Sponsor
- Lead sponsor
- Cairo UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
164 patients will be recruited..Adult patients diagnosed with incurable solid tumors and CCAA who presented to Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK) - Kasr Al-Ainy School of Medicine - Cairo University will be randomly distributed into 1:1..82 will receive Olanzapine 5 mg daily at night and 82 patients will receive placebo for 4 weeks. Primary outcome is Change in loss of appetite score from day 0 to day 7 of treatment and secondary outcomes change in body weight, change in loss of appetite score..and change in quality of life
Conditions
- Anorexia
Interventions
Olanzapine 5 MGDrug
, Olanzapine (OLZ) is an atypical antipsychotic agent that blocks multiple neurotransmitters: dopamine at D1, D2, D3 and D4 brain receptors, serotonin at 5-HT2a , 5-HT2c, 5-HT3, and 5-HT6receptors, catecholamines at alpha 1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors is suggested to have a valuable role in CAC
PlaceboDrug
Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- appetite scoreTime frame: 1 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine
Cairo, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.